Key Takeaways CLOV posted 38% Medicare Advantage enrollment growth and earned a 4-Star CMS rating in Q4 2025.Clover delivered $22M adjusted EBITDA in 2025 and guides up to $70M for 2026.Elevated medical costs and Medicare policy shifts may pressure Clover's margins.Clover Health Investments (CLOV) is well poised for growth in the coming quarters, courtesy of its broad product spectrum. This optimism is primarily driven by its technology-first care model, as evident from solid membership growth, rising reven ...